This Article Full Text Full Text (PDF) Submit a related Letter to the Editor Purchase Article View Shopping Cart Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Copyright Permission Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Stefenelli, T. Articles by Niederle, B. Search for Related Content PubMed PubMed Citation Articles by Stefenelli, T. Articles by Niederle, B. Pubmed/NCBI databases OMIM Compound via MeSH Substance via MeSH Hazardous Substances DB CALCIUM COMPOUNDS CALCIUM, ELEMENTAL Medline Plus Health Information Heart Disease in Women Heart Diseases

Cardiac Abnormalities in Patients with Primary Hyperparathyroidism: Implications for Follow-Up

Department of Cardiology (T.S., H.F., J.K-S., S.G., J.B-K.) and the Department of Surgery, Division of General Surgery (C.A., B.N.), University of Vienna Medical School, Austria

Address correspondence and requests for reprints to: Thomas Stefenelli, MD, FACC, Associate Professor for Internal Medicine, Department of Cardiology, University of Vienna, Währinger Cpürtel 18-20, A-1090-Vienna, Austria.

Patients with primary hyperparathyroidism (PHPT) show a high incidence of left ventricular hypertrophy, cardiac calcific deposits in the myocardium, and/or aortic and mitral valve calcification and thus may carry an increased risk of death from circulatory diseases. This prospective study was designed to assess an effect of parathyroidectomy on cardiac abnormalities of patients with PHPT. Echocardiography was used to evaluate the mechanical performance of the heart muscle, the thickness of the left ventricular wall, myocardial calcific deposits, and valvular calcifications within 12 and 41 months after parathyroidectomy.

In a blinded fashion, aortic and mitral valve calcifications were determined in 46% and 39% of patients with PHPT. Calcific deposits in the myocardium were found in 74% of patients. Follow-up studies after parathyroidectomy disclosed no evidence of progression of these calcifications. Before operation left ventricular hypertrophy was detected in 82%. After parathyroidectomy and 41 months of normocalcemia and normal PTH concentrations, a regression of hypertrophy of the interventricular septum and the posterior wall by -6% and -19% (P < 0.05) was observed. Subgroup analysis disclosed the most impressive long-term reduction of left ventricular hypertrophy in patients without a history of hypertension (-11% and -21%; P < 0.05 and P < 0.005); no changes were determined in 9 patients who developed secondary hyperparathyroidism after operation.

The present data show a high incidence of left ventricular hypertrophy and aortic and/or mitral valve calcifications in patients with PHPT. Follow-up at 1 year and at 41 months after successful parathyroidectomy disclose regression of hypertrophy. Our results give evidence that parathyroid hormone per se plays an important role in the maintainance of myocardial hypertrophy. Post-surgical restoration of normocalcemia and normalization of parathyroid hormone valvular sclerosis persists without evidence of progression. We further conclude that patients with PHPT and parathyroidectomy are at low risk for the development of severe aortic and mitral valve stenosis within this period of time.

This article has been cited by other articles:

				W. Marz, U. Seelhorst, B. Wellnitz, B. Tiran, B. Obermayer-Pietsch, W. Renner, B. O. Boehm, E. Ritz, and M. M. Hoffmann Alanine to Serine Polymorphism at Position 986 of the Calcium-Sensing Receptor Associated with Coronary Heart Disease, Myocardial Infarction, All-Cause, and Cardiovascular Mortality J. Clin. Endocrinol. Metab., June 1, 2007; 92(6): 2363 - 2369. [Abstract] [Full Text] [PDF]

				G. Rashid, J. Bernheim, J. Green, and S. Benchetrit Cardiovascular Events and Parathyroid Hormone--Suggestion of a Further Link J. Am. Soc. Nephrol., April 1, 2007; 18(4): 1023 - 1026. [Abstract] [Full Text] [PDF]

				C. P. Schmitt, T. Odenwald, and E. Ritz Calcium, Calcium Regulatory Hormones, and Calcimimetics: Impact on Cardiovascular Mortality J. Am. Soc. Nephrol., April 1, 2006; 17(4_suppl_2): S78 - S80. [Abstract] [Full Text] [PDF]

				M. R. Rubin, M. S. Maurer, D. J. McMahon, J. P. Bilezikian, and S. J. Silverberg Arterial Stiffness in Mild Primary Hyperparathyroidism J. Clin. Endocrinol. Metab., June 1, 2005; 90(6): 3326 - 3330. [Abstract] [Full Text] [PDF]

				G. J. Strewler A 64-Year-Old Woman With Primary Hyperparathyroidism JAMA, April 13, 2005; 293(14): 1772 - 1779. [Full Text] [PDF]

				P. Andersson, E. Rydberg, and R. Willenheimer Primary hyperparathyroidism and heart disease -- a review Eur. Heart J., October 2, 2004; 25(20): 1776 - 1787. [Abstract] [Full Text] [PDF]

				J. P. Bilezikian and S. J. Silverberg Asymptomatic Primary Hyperparathyroidism N. Engl. J. Med., April 22, 2004; 350(17): 1746 - 1751. [Full Text] [PDF]

				A. P. Shah, A. Lopez, R. Y. Wachsner, S. K. Meymandi, A. K. El-Bialy, and A. M. Ichiuji Sinus Node Dysfunction Secondary to Hyperparathyroidism Journal of Cardiovascular Pharmacology and Therapeutics, April 1, 2004; 9(2): 145 - 147. [Abstract] [PDF]

				F.N Saleh, H Schirmer, J Sundsfjord, and R Jorde Parathyroid hormone and left ventricular hypertrophy Eur. Heart J., November 2, 2003; 24(22): 2054 - 2060. [Abstract] [Full Text] [PDF]

				F. Fallo, G. Camporese, E. Capitelli, G. M. Andreozzi, F. Mantero, and F. Lumachi Ultrasound Evaluation of Carotid Artery in Primary Hyperparathyroidism J. Clin. Endocrinol. Metab., May 1, 2003; 88(5): 2096 - 2099. [Abstract] [Full Text] [PDF]

				S. J. Marx Hyperparathyroid and Hypoparathyroid Disorders N. Engl. J. Med., December 21, 2000; 343(25): 1863 - 1875. [Full Text] [PDF]

				G.Y.H Lip, D.C Felmeden, F.L Li-Saw-Hee, and D.G Beevers Hypertensive heart disease. A complex syndrome or a hypertensive 'cardiomyopathy'? Eur. Heart J., October 2, 2000; 21(20): 1653 - 1665. [PDF]

				Shonni J. Silverberg; Cardiovascular Disease in Primary Hyperparathyroidism J. Clin. Endocrinol. Metab., October 1, 2000; 85(10): 3513 - 3514. [Full Text]

				J. C. Smith, M. D. Page, R. John, M. H. Wheeler, J. R. Cockcroft, M. F. Scanlon, and J. S. Davies Augmentation of Central Arterial Pressure in Mild Primary Hyperparathyroidism J. Clin. Endocrinol. Metab., October 1, 2000; 85(10): 3515 - 3519. [Abstract] [Full Text]

				H. G. Bone Who Needs Parathyroid Surgery? The Case for Parathyroidectomy in Nonclassical Primary Hyperparathyroidismb J. Clin. Endocrinol. Metab., July 1, 1999; 84(7): 2278 - 2282. [Full Text]

				T. Neunteufl, R. Katzenschlager, C. Abela, Karam Kostner, B. Niederle, F. Weidinger, and T. Stefenelli Impairment of endothelium-independent vasodilation in patients with hypercalcemia Cardiovasc Res, November 1, 1998; 40(2): 396 - 401. [Abstract] [Full Text] [PDF]

				J. A. Sosa, N. R. Powe, M. A. Levine, R. Udelsman, and M. A. Zeiger Thresholds for Surgery and Surgical Outcomes for Patients with Primary Hyperparathyroidism: A National Survey of Endocrine Surgeons J. Clin. Endocrinol. Metab., August 1, 1998; 83(8): 2658 - 2665. [Abstract] [Full Text]

				R. Nehgme, J. T. Fahey, C. Smith, and T. O. Carpenter Cardiovascular Abnormalities in Patients with X-Linked Hypophosphatemia J. Clin. Endocrinol. Metab., August 1, 1997; 82(8): 2450 - 2454. [Abstract] [Full Text] [PDF]